Why U.S. HealthTech Funding in 2026 Favors Infrastructure Over Apps

By 2026, less than 1 in 5 U.S. healthtech startups that raise a Seed round will successfully raise a Series B.

Not because the technology fails.
Not because the market isn’t large enough.

But because most founders are still building apps, while U.S. capital has moved decisively toward infrastructure.

The winners are no longer the teams with the best UI or the most downloads.
They are the teams that sit inside workflows, prove revenue ownership, create switching costs, and align with buyers that are actually acquiring.

This is the structural shift shaping U.S. healthtech funding in 2026.

UNITED STATES — 2026 HEALTH TECH SCALING & FUNDING MAP

This map explains why U.S. VCs fund infrastructure—not apps—and how founders can position themselves to raise, scale, and exit in this ecosystem.

The system breaks down into four layers.

1️⃣ Workflow Infrastructure

Where usage becomes unavoidable

In 2026, U.S. investors prioritize companies that are embedded into daily operational workflows—not optional tools.

These businesses:

• Live inside EHRs, revenue workflows, staffing systems, or clinical operations

• Expand as volume grows

• Are painful to remove once adopted

Why this layer matters
Workflow insertion is the fastest path to:

• Expansion revenue

• Long-term contracts

• Low churn

Founder mistake
Pitching workflow “adjacency” instead of workflow ownership.

Winning system

• Start with one operational choke point

• Integrate deeply before expanding horizontally

• Tie adoption to operational KPIs, not engagement metrics

Companies embedded inside hospital, payer, or enterprise workflows that scale with volume — not users.

18 active U.S. companies 

1. Abridge

2. Augmedix

3. Notable

4. Qventus

5. LeanTaaS

6. Kyruus Health

7. Relatient

8. Health Catalyst

9. Innovaccer

10. Cedar

11. AKASA

12. Artera

13. PatientPoint

14. Olive AI (restructured, assets active)

15. Clarify Health

16. Arcadia

17. Exponential AI (health ops)

18. Cohere Health

Why VCs fund this layer:
Embedded usage + expansion revenue + operational lock-in.

2️⃣ Revenue Infrastructure

Where fundraising becomes possible

U.S. VCs are no longer impressed by ARR alone.
They want clarity on who pays, why they pay, and how revenue compounds.

Revenue infrastructure companies:

• Reduce leakage

• Enable reimbursement

• Protect margins under payer pressure

• Make CFOs care

Why this layer matters
This is where companies move from “interesting” to fundable at scale.

Founder mistake
Treating revenue as a downstream outcome instead of a designed system.

Winning system

• Map the full revenue journey (from service delivered → dollar captured)

• Align value to budget owners early

• Translate clinical or operational impact into financial outcomes

Companies that prove where money comes from, reduce leakage, or unlock reimbursement — especially under margin pressure.

18 active U.S. companies

1. Waystar

2. FinThrive

3. Experian Health

4. Zelis

5. Inovalon

6. HealthEdge

7. Milliman MedInsight

8. ClosedLoop.ai

9. Carta Healthcare

10. CorroHealth

11. Nym Health

12. Codametrix

13. AKASA (revenue-only footprint)

14. Optum Financial (unit-level infra)

15. Collectly

16. Flywire Health

17. R1 RCM

18. Exl Health Analytics

Why VCs fund this layer:
Direct line to dollars → fastest path to profitable scale.

3️⃣ Defensibility Infrastructure

Where valuations are protected

In 2026, defensibility matters more than growth rate.

Defensible healthtech companies typically have:

• Data gravity

• Regulatory depth

• Long-term contracts

• Switching costs that increase over time

Why this layer matters
This is where:

• Late-stage capital concentrates

• Down-round risk drops

• Strategic buyers start paying attention

Founder mistake
Confusing “complex” with “defensible”.

Winning system

• Make replacement expensive, not just inconvenient

• Build compliance and trust as product features

• Design for durability, not speed alone

Data gravity, switching costs, compliance depth — hard to replace, expensive to unwind.

18 active U.S. companies

1. Datavant

2. HealthVerity

3. Komodo Health

4. Truveta

5. Veradigm

6. Redox

7. Particle Health

8. Health Gorilla

9. ClearData

10. Imprivata

11. Censinet

12. Fortified Health Security

13. OneTrust (health vertical)

14. TrustArc

15. Veeva Systems (health cloud infra)

16. IQVIA (data infra arm)

17. Snowflake Healthcare

18. Palantir Foundry for Health

Why VCs fund this layer:
Durability > growth rate. This is where late-stage capital concentrates.

4️⃣ Active Buyers

Where exits actually happen

This is the most misunderstood layer.

In 2026, apps are rarely acquired.
Infrastructure is.

Active buyers are looking for:

• Workflow control

• Revenue rails

• Data platforms

• Cost-reduction engines

They acquire to:

• Consolidate fragmented markets

• Protect margins

• Control distribution

Founder mistake
Building for hypothetical exits instead of observable acquisition behavior.

Winning system

• Track who is buying—not who is famous

• Design product and contracts to fit acquisition logic

• Build optionality early (strategic + financial)

These are companies that have actually acquired, rolled up, or publicly stated intent to buy infrastructure assets in the last 24–36 months.

18 real, active acquirers (recent behavior)

1. R1 RCM (rolling up automation & analytics)

2. Waystar (post-IPO consolidation)

3. Roper Technologies (health IT roll-ups)

4. Francisco Partners (RCM + data buyouts)

5. Thoma Bravo (health software PE)

6. Bain Capital (health infra platforms)

7. Insight Partners (late-stage infra)

8. Vista Equity Partners (workflow SaaS)

9. General Atlantic (health platforms)

10. Walgreens Boots Alliance (care + data assets)

11. CVS Health (services + infra acquisitions)

12. Elevance Health (care enablement assets)

13. UnitedHealth Group (selective infra)

14. Labcorp (data + diagnostics platforms)

15. Quest Diagnostics (digital + analytics)

16. Thermo Fisher Scientific (research infra)

17. Siemens Healthineers (software + data)

18. GE HealthCare (AI + workflow acquisitions)

Why this matters:
These buyers do not buy apps.
They buy revenue rails, data systems, and workflow control points.

The missing link: turning the map into execution

Most founders understand these layers conceptually.

Where they struggle is execution:

• Translating the map into a build roadmap

• Aligning product, GTM, and fundraising

• Avoiding infrastructure debt while scaling

• Positioning the company for the right capital at the right time

This is the gap between:

“We know what we should build”
and
“We raised, scaled, and converted interest into contracts.”

That gap is system design.

How founders win in this ecosystem (the framework)

The teams that scale and raise in the U.S. in 2026 follow a repeatable system:

1. Anchor in one infrastructure layer first

2. Prove operational or financial ownership

3. Add defensibility before scaling GTM

4. Align early with real buyer logic

This is not about speed.
It’s about sequence.

Final thought

U.S. healthtech in 2026 is no longer an app economy.
It’s an infrastructure economy.

Founders who understand—and build for—this reality:

• Raise with less dilution

• Scale with fewer pivots

• Exit with options, not hope

The rest will keep wondering why traction isn’t translating into funding.